探索使用HPV初级筛查对HPV疫苗影响的人群监测策略

IF 4.7 Q1 VIROLOGY Tumour Virus Research Pub Date : 2023-06-01 DOI:10.1016/j.tvr.2023.200255
Louiza S. Velentzis , David Hawkes , Michael Caruana , Julia ML. Brotherton , Megan A. Smith , Lara Roeske , Khurram A. Karim , Suzanne M. Garland , C. David Wrede , Jeffery Tan , Cosette Wheeler , Philip E. Castle , Marion Saville , Karen Canfell
{"title":"探索使用HPV初级筛查对HPV疫苗影响的人群监测策略","authors":"Louiza S. Velentzis ,&nbsp;David Hawkes ,&nbsp;Michael Caruana ,&nbsp;Julia ML. Brotherton ,&nbsp;Megan A. Smith ,&nbsp;Lara Roeske ,&nbsp;Khurram A. Karim ,&nbsp;Suzanne M. Garland ,&nbsp;C. David Wrede ,&nbsp;Jeffery Tan ,&nbsp;Cosette Wheeler ,&nbsp;Philip E. Castle ,&nbsp;Marion Saville ,&nbsp;Karen Canfell","doi":"10.1016/j.tvr.2023.200255","DOIUrl":null,"url":null,"abstract":"<div><p>Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec’2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vaccination benchmark prevalence. Pre-vaccination samples (2005–2008) (n = 1933; WHINURS), from 25 to 64-year-old women had been previously analysed with Linear Array (LA). Post-vaccination samples (2013-2014) (n = 2989; Compass pilot), from 25 to 64-year-old women, were analysed by cobas 4800 (cobas), and by LA for historical comparability. Age standardised pre-vaccination HPV16/18 prevalence was 4.85% (95%CI:3.81–5.89) by LA; post-vaccination estimates were 1.67% (95%CI:1.21–2.13%) by LA, 1.49% (95%CI:1.05–1.93%) by cobas, and 1.63% (95%CI:1.17–2.08%) for cobas and LA testing of non-16/18 cobas positives (cobas/LA). Age-standardised pre-vaccination oncogenic HPV prevalence was 15.70% (95%CI:13.79–17.60%) by LA; post-vaccination estimates were 9.06% (95%CI:8.02–10.09%) by LA, 8.47% (95%CI:7.47–9.47%) by cobas and cobas/LA. Standardised rate ratios between post-vs. pre-vaccination rates were significantly different for HPV16/18, non-16/18 HPV and oncogenic HPV: 0.34 (95%CI:0.23–0.50), 0.68 (95%CI:0.55–0.84) and 0.58 (95%CI:0.48–0.69), respectively. Additional strategies (LA for all cobas positives; combined cobas and LA results on all samples) had similar results. If a single method is applied consistently, it will provide important data on relative changes in HPV prevalence following vaccination.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"15 ","pages":"Article 200255"},"PeriodicalIF":4.7000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/c2/main.PMC9925607.pdf","citationCount":"0","resultStr":"{\"title\":\"Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening\",\"authors\":\"Louiza S. Velentzis ,&nbsp;David Hawkes ,&nbsp;Michael Caruana ,&nbsp;Julia ML. Brotherton ,&nbsp;Megan A. Smith ,&nbsp;Lara Roeske ,&nbsp;Khurram A. Karim ,&nbsp;Suzanne M. Garland ,&nbsp;C. David Wrede ,&nbsp;Jeffery Tan ,&nbsp;Cosette Wheeler ,&nbsp;Philip E. Castle ,&nbsp;Marion Saville ,&nbsp;Karen Canfell\",\"doi\":\"10.1016/j.tvr.2023.200255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec’2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vaccination benchmark prevalence. Pre-vaccination samples (2005–2008) (n = 1933; WHINURS), from 25 to 64-year-old women had been previously analysed with Linear Array (LA). Post-vaccination samples (2013-2014) (n = 2989; Compass pilot), from 25 to 64-year-old women, were analysed by cobas 4800 (cobas), and by LA for historical comparability. Age standardised pre-vaccination HPV16/18 prevalence was 4.85% (95%CI:3.81–5.89) by LA; post-vaccination estimates were 1.67% (95%CI:1.21–2.13%) by LA, 1.49% (95%CI:1.05–1.93%) by cobas, and 1.63% (95%CI:1.17–2.08%) for cobas and LA testing of non-16/18 cobas positives (cobas/LA). Age-standardised pre-vaccination oncogenic HPV prevalence was 15.70% (95%CI:13.79–17.60%) by LA; post-vaccination estimates were 9.06% (95%CI:8.02–10.09%) by LA, 8.47% (95%CI:7.47–9.47%) by cobas and cobas/LA. Standardised rate ratios between post-vs. pre-vaccination rates were significantly different for HPV16/18, non-16/18 HPV and oncogenic HPV: 0.34 (95%CI:0.23–0.50), 0.68 (95%CI:0.55–0.84) and 0.58 (95%CI:0.48–0.69), respectively. Additional strategies (LA for all cobas positives; combined cobas and LA results on all samples) had similar results. If a single method is applied consistently, it will provide important data on relative changes in HPV prevalence following vaccination.</p></div>\",\"PeriodicalId\":52381,\"journal\":{\"name\":\"Tumour Virus Research\",\"volume\":\"15 \",\"pages\":\"Article 200255\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/c2/main.PMC9925607.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tumour Virus Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666679023000022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumour Virus Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666679023000022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

2017年12月,澳大利亚的宫颈筛查项目从细胞学转向HPV检测,并对HPV16/18进行基因分型。我们调查了计划数据是否可用于监测HPV疫苗接种计划(始于2007年)对HPV16/18流行率的影响,并将估计值与疫苗接种前的基准流行率进行了比较。疫苗接种前样本(2005-2008年)(n=1933;WHINURS),来自25至64岁女性,之前曾使用线性阵列(LA)进行过分析。通过cobas 4800(cobas)和LA对25至64岁女性的疫苗接种后样本(2013-2014)(n=2989;Compass试点)进行了历史可比性分析。LA的年龄标准化疫苗接种前HPV16/18患病率为4.85%(95%CI:3.81-5.89);LA的疫苗接种后估计值为1.67%(95%CI:1.21–2.13%),cobas的疫苗接种估计值为1.49%(95%CI:1.05–1.93%),cobas和LA检测非16/18 cobas阳性(cobas/LA)的疫苗接种预测值为1.63%(95%CI:1.17–2.08%)。LA的年龄标准化接种前致癌HPV患病率为15.70%(95%CI:13.79–17.60%);LA的疫苗接种后估计值为9.06%(95%CI:8.02–10.09%),cobas和cobas/LA的估计值为8.47%(95%CI:7.47–9.47%)。后与。HPV16/18、非16/18型HPV和致癌HPV的疫苗接种前率显著不同:分别为0.34(95%CI:0.23–0.50)、0.68(95%CI:0.55–0.84)和0.58(95%CI=0.48–0.69)。其他策略(所有cobas阳性的LA;所有样本的cobas和LA组合结果)具有相似的结果。如果持续应用单一方法,它将提供有关接种疫苗后HPV患病率相对变化的重要数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening

Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec’2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vaccination benchmark prevalence. Pre-vaccination samples (2005–2008) (n = 1933; WHINURS), from 25 to 64-year-old women had been previously analysed with Linear Array (LA). Post-vaccination samples (2013-2014) (n = 2989; Compass pilot), from 25 to 64-year-old women, were analysed by cobas 4800 (cobas), and by LA for historical comparability. Age standardised pre-vaccination HPV16/18 prevalence was 4.85% (95%CI:3.81–5.89) by LA; post-vaccination estimates were 1.67% (95%CI:1.21–2.13%) by LA, 1.49% (95%CI:1.05–1.93%) by cobas, and 1.63% (95%CI:1.17–2.08%) for cobas and LA testing of non-16/18 cobas positives (cobas/LA). Age-standardised pre-vaccination oncogenic HPV prevalence was 15.70% (95%CI:13.79–17.60%) by LA; post-vaccination estimates were 9.06% (95%CI:8.02–10.09%) by LA, 8.47% (95%CI:7.47–9.47%) by cobas and cobas/LA. Standardised rate ratios between post-vs. pre-vaccination rates were significantly different for HPV16/18, non-16/18 HPV and oncogenic HPV: 0.34 (95%CI:0.23–0.50), 0.68 (95%CI:0.55–0.84) and 0.58 (95%CI:0.48–0.69), respectively. Additional strategies (LA for all cobas positives; combined cobas and LA results on all samples) had similar results. If a single method is applied consistently, it will provide important data on relative changes in HPV prevalence following vaccination.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Tumour Virus Research
Tumour Virus Research Medicine-Infectious Diseases
CiteScore
6.50
自引率
2.30%
发文量
16
审稿时长
56 days
期刊最新文献
Modulation of epithelial homeostasis by HPV using Notch and Wnt. Modulation of connexin 43 in viral infections The imprint of viral oncoproteins on the variable clinical behavior among human papilloma virus-related oropharyngeal squamous cell carcinomas Genomic diversity of HPV6 and HPV11 in recurrent respiratory papillomatosis: Association with malignant transformation in the lungs and clinical outcomes The SV40 virus enhancer functions as a somatic hypermutation-targeting element with potential tumorigenic activity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1